A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

X. Pivot, P. Koralewski, J.L. Hidalgo, A. Chan, A. Gonçalves, G. Schwartsmann, S. Assadourian, J.P. Lotz

Open source

DOI: 10.1093/annonc/mdn171
Published: 2008-09
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/annonc/mdn171,
  title = {A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients},
  author = {X. Pivot and P. Koralewski and J.L. Hidalgo and A. Chan and A. Gonçalves and G. Schwartsmann and S. Assadourian and J.P. Lotz},
  year = {2008},
  journal = {Annals of Oncology},
  doi = {10.1093/annonc/mdn171},
  url = {https://doi.org/10.1093/annonc/mdn171}
}

RIS

TY  - JOUR
TI  - A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
AU  - X. Pivot
AU  - P. Koralewski
AU  - J.L. Hidalgo
AU  - A. Chan
AU  - A. Gonçalves
AU  - G. Schwartsmann
AU  - S. Assadourian
AU  - J.P. Lotz
PY  - 2008
JO  - Annals of Oncology
DO  - 10.1093/annonc/mdn171
UR  - https://doi.org/10.1093/annonc/mdn171
ER  -

APA

Pivot, X., Koralewski, P., Hidalgo, J., Chan, A., Gonçalves, A., Schwartsmann, G., Assadourian, S., & Lotz, J. (2008). A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Annals of Oncology. https://doi.org/10.1093/annonc/mdn171

Source records

crossref · retrieved 2026-09-25T23:41:52.180Z